Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 19, 2009 - Issue 6
Submit an article Journal homepage
148
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Improving antidepressant drugs: update on recently patented compounds

Isabel Rozas University of Dublin, School of Chemistry, Trinity College, Dublin 2, Ireland +353 18963731; +353 16712826; [email protected]
Pages 827-845 | Published online: 28 May 2009

Bibliography

  • Available from: http://www.who.int/mental_health/management/depression/definition/en/
  • Mental Health Global Action Programme. Close the gap, dare to care. Geneva: World Health Organization; 2002
  • Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:435-51
  • Frazer A. Antidepressants. J Clin Psychiatr 1997;58:9-25
  • Millan MJ. The role of monoamines in the actions of established and «novel» antidepressant agents: a critical review. Eur J Pharmacol 2004;500:371-84
  • Invernizzi RW, Garattini S. Role of presynaptic α2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuro Psychopharmacol Biol Psychiatry 2004;28:819-27
  • Butler SG, Meegan MJ. Recent development in the design of anti-depressive therapies: targeting the serotonin transporter. Curr Med Chem 2008;15:1737-61
  • Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137-51
  • Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
  • Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77
  • Rasmussen K. Creating more effective antidepressants: clues from the clinic. Drug Discov Today 2006;11:623-31
  • Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004;29:126-33
  • Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augementation strategies. J Clin Psychiatry 1998;59(Suppl 5):60-3
  • Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997;12(Suppl 3):S7-14
  • Schmidt HD, Banasr M, Duman RS. Future antidepressant targets: neurotrophic factors and related signaling cascades. Drug Discov Today Ther Strateg 2008;5:151-6
  • EPO searching engine. Available from: http://ep.espacenet.com/
  • Nencetti S, Lapucci A. 4-Arylpiperidine derivatives and use thereof for preparing a medicament for the treatment of CNS disorders. WO2006106432; 2006
  • Gerdes JM, Bolstad DB. Enantiomers of 2′-fluoralkyl-6-nitroquipazine as Serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics. WO2007127262; 2007
  • Shanghai INST. Pharm. Industry. Aralkyl-alcohol piperazine derivatives adn their uses as antgyepressant. US2005267121; 2005
  • Gruenenthal GMBH. New substituted 1-oxo-3,8-diazospiro(4.5)-decan-2-one compounds are 5-hydroxy tryptamine uptake receptor inhibitors, useful to treat and/or prevent e.g. pain, migraine, chronic paroxysomal hemicrania, depression and asthma. DE102005030051; 2006
  • Lundbeck & Co As. 2-(1H-indolylsulfanyl)-benzyl amine derivative. P2007277254; 2007
  • Natco Pharma Ltd. 3-Aryloxy 3-Substituted Propanamines. WO2008081477; 2008
  • Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-7
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxan methylamines. KR20050061470; 2005
  • Wyeth Corp. Antidepressant piperidine derivatives of heterocycle-fused benzodioxans. KR20050042192; 2005
  • Wyeth Corp. Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans. KR20050042187; 2005
  • Wyeth Corp. Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines. KR20050042176; 2005
  • Wyeth Corp. Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans. MXPA05002743; 2005
  • Wyeth Corp. Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan. MXPA05002740; 2005
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-dioxa-3-aza-cyclopenta[a]naphtalene. MXPA03009829; 2005
  • Wyeth Corp. Antidepressant (SSRI) azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1, 3-diazacyclopenta[a]naphtalene. MXPA03009828; 2005
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinaxoline. MXPA03009826; 2005
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans. MXPA03009825; 2005
  • Wyeth Corp. Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxans. EP1537103; 2005
  • Wyeth Corp. Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole. WO02088146; 2005
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene. US2005228010; 2005
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene. US2005004209; 2005
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans. ZA200502043; 2006
  • Wyeth Corp. Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans. ZA200502047; 2006
  • Wyeth Corp. Antidepressant piperidine derivatives of heterocycle-fused benzodioxans. ZA200502042; 2006
  • Wyeth Corp. Antidepressant indolealkyl derivatives of heterocyclefused benzodioxan methylamines. ZA200502040; 2006
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans. US2006293301; 2006
  • Wyeth Corp. Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans. US2006276481; 2006
  • Wyeth Corp. Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans. NZ539253; 2006
  • Wyeth Corp. Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan. US2006160881; 2006
  • Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans. US2007004702; 2007
  • Wyeth Corp. Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans. WO2008150848; 2008
  • Wyeth Corp. Antidepressant indolealkyl derivatives of heterocyclefused benzodioxan methylamines. CN101143867; 2008
  • Wyeth Corp. Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans. CN101239953; 2008
  • Wyeth Corp. Antidepressant piperidine derivatives of heterocycle-fused benzodioxans. CN101230066; 2008
  • Cheetham SC, Viggers JA, Slater NA, et al. [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 1993;32:737-43
  • Hall MD, El Mestikawy S, Emerit MB, et al. [3H]8-Hydroxy-2-(di-n-propylamino)tetraline binding to pre- and postsynaptic 5-Hydroxytryptamine sites in various regions of the rat brain. J Neurochem 1985;44:1685-96
  • Merck Patent GmbH. Derivatives of pyridinalkyl-amonoalkyl-1h-indole inhibiting receptors 5-ht and recapture of serotonin which can be used as antidepressant and anxiolitic. KR20050085038; 2005
  • Merck Patent GmbH. Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs. PL377618; 2006
  • Merck Patent GmbH. Indole derivatives as serotonin reuptake inhibitors. MXPA05013538; 2006
  • UCB SA. 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments. MXPA05003290; 2005
  • UCB SA. Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases. EP1693061; 2006
  • Ge JA, Barnes NM. 5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. Br J Pharmacol 1996;117:1475-80
  • Lucas G, Debonnel G. 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur J Neurosci 2002;16:817-22
  • Lucas G, Compan V, Charnay Y, et al. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry 2005;57:918-925
  • Lucas G, Rymar VV, Du J, et al. Serotonin(4) (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007;55:712-25
  • Debonnel G, Lucas G. Stimulators of 5-ht4 receptors and uses thereof. WO2006029520; 2006
  • Heinrich T, Bottcher H. Indole derivatives as serotonin reuptake inhibitors. US2006160824; 2006
  • Pinney KG, Miranda MG. Serotonin reuptake inhibitors. WO2005094896; 2005
  • Pinney KG, Miranda MG. Serotonin reuptake inhibitors. US2008132514; 2008
  • Janssen Pharmaceutica. C–substituted tricyclic isoxazoline derivatives and their use as anti-depressants. US2005256119; 2005
  • Alpha 2 Pharmaceutical. Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor. WO2006083204; 2006
  • Alpha 2 Pharmaceutical. Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor. US2008269306; 2008
  • Soares JC, Innis RB. Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 1999;46:600-15
  • Lilly Co. Eli. Combination therapy for treatment of psychoses. EP830864; 1997
  • Feenstra R, Ronken E, Koopman T, et al. SLV308. antiparkinsonian, antidepressant, anxiolytic, dopamine D2 partial agonist, 5-HT1A agonist. Drugs Future 2001;26:128-32
  • Solvay Pharmaceuticals BV. New phenylpiperazines useful for treating central nervous system disorders caused by dopaminergic or serotonergic systems. NZ523135; 2005
  • Solvay Pharmaceuticals BV. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. US2006122189, US2006122190, US2006247256; 2006
  • Solvay Pharmaceuticals BV. Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. US2006122175, CA2587940; 2006
  • Solvay Pharmaceuticals BV. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptakesites. US2006122177. CA2587928; 2006
  • Solvay Pharmaceuticals BV. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. US2006122206, CA2587936; 2006
  • Solvay Pharmaceuticals BV. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. US2006122247; 2006
  • Solvay Pharmaceuticals BV. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. EP1824479, EP1824480, EP1827426, EP1828161, MX2007006818; 2007
  • Solvay Pharmaceuticals BV. Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. EP1824486, MX2007006758; 2007
  • Solvay Pharmaceuticals BV. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. EP1828168, MX2007006757; 2007
  • Solvay Pharmaceuticals BV. 8-{4-[3-(5-fluoro-1H-indol-3-YLl)-propyl]-piperazin-1-YL)-2-methyl-4H-benzo[1,4].oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site. AU2002250983; 2006
  • Solvay Pharmaceuticals BV. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. SI1827427; 2008
  • Solvay Pharmaceuticals BV. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. MX2007006756; 2007
  • Solvay Pharmaceuticals BV. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. HR20090015; 2009
  • Squibb Bristol Myers Co. Antipsychotic heterocycle compounds. EP1598068; 2005
  • Sindrup J. Anesthesia: Biological foundations. In: Yaksh TL, Lynch C, Zapol W, et al. Philadelphia: Lippincott-Raven; 1997
  • Gruenenthal GmbH. C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorder. US2006258741; 2006
  • Maggi CA. The troubled story of tachykinins and neurokinins. Trends Pharmacol Sci 2000;21:173-5
  • Ryckmans T, Balançon L, Berton O, et al. First dual NK1 antagonists serotonin reuptake inhibitors: synthesis and SAR of a new class off potential antidepressants. Bioorg Med Chem Lett 2002;12:261-4
  • Servier Lab. Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists. EP1710240; 2006
  • Sanofi Aventis. Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them. EP1707564; 2006
  • Edmonds-Alt X, Vilain P, Goulaouic P, et al. A potent and selective non-peptide antagonist of the neurokinin a (NH2) receptor. Life Sci 1992;50:PL101-6
  • Sanofi Aventis. Composition useful to treat e.g. anxiety disorder comprises (S)-(-)-N-(4-(4-acetamido-4-phenyl- 1-piperidyl)-2-(3, 4-dichlorophenyl) butyl)-N-methylbenzamide, (+/-)-N-methyl-3-phenyl- 3-(4-(trifluoromethyl)phenoxy)-propan- 1-amine. FR2904221; 2008
  • Padgett LW. Recent developments in cannabinoid ligands. Life Sci 2005;77:1767-98
  • Muccioli GG, Lambert DM. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem 2005;12:1361-94
  • Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005;48:5059-87
  • Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005;81:331-42
  • Solvay Pharmaceuticals BV. Compounds with a combination of cannabinoid cb1 antagonism and serotonin reuptake inhibition. US2008214559, WO2008084057; 2008
  • Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997;36:419-28
  • SmithKline Beecham PLC, Jones BJ, Routledge C. Composition containing 5-HT1A and 5-HTID antagonists. WO9531988; 1995
  • Maura G. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate and inhibition of cyclic GMP production in rat cerebellum in vitro. J Neurochem 1996;66:203-9
  • Pfizer Prod., Inc. 5HT1 antagonists for antidepressant therapy. OA11742; 2005
  • Merck Patent GmbH. New 3-oxo-1-propenyl azo compounds useful as 5-HT receptor antagonists e.g. for treating psychoses, neurological disorders, amyotrophic lateral sclerosis and eating disorders. DE10360151; 2005
  • Merck Patent GmbH. New quinolonyl- or benzopyranonyl-substituted indole derivatives are 5HT(1A)- and/or 5HT(1D)-agonists useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents. DE10353657; 2005
  • Esteve Labor Dr. New tetrahydroisoquinoline substituted sulfonamide compounds useful as 5-HT7 receptor antagonist in the treatment of e.g. central nervous system disorders. ES2257168; 2006
  • Esteve Labor Dr. New dihydro-1H-isoquinoline compounds are 5-hydroxytryptamine-7 inhibitors useful for the treatment of e.g. sleep disorder, shift worker syndrome, depression, migraine, anxiety, psychosis, schizophrenia and pain. ES2257167; 2006
  • Terrón JA. The 5HT7 receptor: a target for novel therapeutic avenues? IDrugs 1998;1:302-10
  • Lovenberg TW, Baron BM, de Lecea L, et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of circadian rhythms. Neuron 1993;11:449-58
  • Esteve Labor Dr. New indene derivatives useful for treating e.g. obesity, bulimia, anorexia, cachexia, diabetes, anxiety, panic attacks, depression and bipolar disorders. ES2274725; 2007
  • Yoshioka M, Matsumoto M, Togashi H, et al. Central distribution and function of 5-HT(6) receptor subtype in the rat brain. Ann NY Acad Sci 1998;861:244
  • Bourson A, Boess FG, Bos M, et al. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 1998;125:1562-6
  • Rogers DC, Robinson TL, Quilter CA, et al. Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br J Pharmacol Suppl S 1999;127:22P
  • Branchek TA, Blackburn TP. 5-HT6 receptors as emerging targets for drug discovery. Ann Rev Pharmacol Toxicol 2000;40:319-34
  • Routledge C, Bromidge SM, Moss SF, et al. Characterization of SB-271046: A potent, selective and orally active 5-HT6 receptor antagonist. Br J Pharmacol 2000;130:1606-12
  • Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-10
  • Glatt CE, Snowman AM, Sibley DR, et al. Clozapine − selective labeling of sites resembling 5ht(6) serotonin receptors may reflect psychoactive profile. Mol Med 1995;1:398-406
  • Monsma FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high-affinity for tricyclic psychotropic-drugs. Mol Pharmacol 1993;43:320-7
  • Shinkai T, Ohmori O, Kojima H, et al. et al. Association study of the 5-HT6 receptor gene in schizophrenia. Am J Med Genet 1999;88:120-2
  • Egis Gyogyszergyar Nyilvanosan. Pyridine derivatives of alkyloxindoles as 5-HT7 receptor active agents. HU0500462; 2007
  • Egis Gyogyszergyar Nyilvanosan. Pyperazine derivatives of alkyl-oxindoles. HU0500461; 2007
  • Egis Gyogyszergyar Nyilvanosan. Pyridine derivatives of dialkyl-oxindoles. HU0500463; 2007
  • Egis Gyogyszergyar Nyilvanosan. Piperazine derivatives of dialkyl-oxindoles. HU0500464; 2007
  • Fourtillan SNC. New 1-hydroxy- 3-oxo-propen-1-yl-hexahydro-pyrrolo-indole compounds are 5-hydroxy tryptamine-2 receptor antagonists useful to treat e.g. depression, anxiety, Parkinson's disease, Alzheimer's diseases, cancer, skin diseases and anxiety. FR2912747; 2008
  • Fourtillan SNC. New 3H,11H-oxazolo(3′,4′:1,2)pyrido(3,4-b)indole derivatives are 5-hydroxytryptamine- 2 receptor activators useful e.g. to treat insomnia, jet lag, anxiety, depression and Alzheimers. FR2908767; 2008
  • Callado LF, Meana JJ, Grijalba B, et al. Selective increase of alpha2a-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 1998;70:1114-23
  • Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, et al. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: Selective supersensitivity of alpha2A-adrenoceptors. Mol Psychiatry 2002;7:755-67
  • Mateo Y, Fernandez-Pastor B, Meana JJ. Acute and chronic effects of desipramine and clorgyline on alpha2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 2001;133:1362-70
  • Fernandez-Pastor B, Meana JJ. In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic alpha2-adrenoceptors. Eur J Pharmacol 2002;442:225-9
  • Devoto P, Flore G, Pani L, Gessa GL. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 2001;6:657-64
  • Mateo Y, Pineda J, Meana JJ. Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J Neurochem 1998;71:790-8
  • Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009;43:215-229
  • Rozas I, Rodriguez F, et al. Guanidine based Compounds. EP2008068199; 2008
  • Rozas I, Rodriguez F, et al. α2-Adrenoceptor Ligands. UK08234205; 2008
  • Van Der Burg WJ. Psychofarmaceutical Preparation. WO2006006858; 2006
  • Gmeiner P, Huebner H. New N-substituted 1-benzyl-1H-(1,2,3)- triazole-4-carboxamides, are dopamine and alpha-1 adrenergic receptor ligands useful for treating diseases of the urinary tract, vascular system or CNS. DE102004039065; 2006
  • Millan MJ, Bervoets K, Rivet JM, et al. Multiple alpha-2-adrenergic receptor subtypes .2. Evidence for a role of rat r(alpha-2a), adrenergic-receptors in the control of nociception, motor behavior and hippocampal synthesis of nor adrenaline. J Pharmacol Exp Ther 1994;270:958-72
  • Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram. Eur J Neurosci 2000;12:1079-95
  • Gobert A, Di Cara B, Cistarelli L, et al. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha(2A)-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther 2003;305:338-46
  • Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997;36:609-20
  • Servier Lab. Benzoindoline derivatives with adrenergic activity. EP1516871; 2005
  • Kinney GG, Sur C. Glycine site modulators and glycine transporter-1 inhibitors as novel therapeutic targets for the treatment of schizophrenia. Curr Neuropharmacol 2005;3:35-43
  • Tech Egon. Combating stress states or nervous system or metabolic disorders, using glycine as neurotransmission modulator showing antistress, stress protective, nootropic and toxin binding actions. DE102005027905; 2005
  • Sanofi Aventis. New N-heterocyclylmethyl benzamide derivatives useful as glycine transporter inhibitors for e.g. treating dementia-associated behavioral problems, psychoses, anxiety, depression and alcohol abuse. FR2861076; 2005
  • Sanofi Aventis. Use of tricyclic compounds as glycine transport inhibitors. CN1882587; 2006
  • Swanson CJ, Bures M, Johnson MP, et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev Drug Discov 2005;4:131-44
  • Nazakato A, Chaki S. 6-Fluorobicyclo[3.1.0]hexane derivatives. US2005119345; 2005
  • Servier Lab. Fluorinated benzothiadiazine derivatives and their use as AMPA receptor modulators. EP1557412; 2005
  • Servier Lab. Benzothiazine and benzothiadiazine derivatives, process for their preparation and phamaceutical compositions containing them. EP1669072; 2006
  • Servier Lab. Benzothiadiazine derivatives, method for preparing them and pharmaceutical compositions containing them. EP1655030; 2006
  • Servier Lab. Benzothiadiazine derivatives, process of preparation thereof and pharmaceutical compositions containing them. EP1655299; 2006
  • Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann NY Acad Sci 2003;1003:292-308
  • Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003;1003:250-72
  • Gozin M, Weiner HL. Novel neuroprotective compounds and uses thereof. WO2006077597; 2006
  • Hermann HL. Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder. DE102007009888; 2008
  • Hatt H, Kragler A. Use of 1,3-dioxane derivatives to enhance the activity of gamma-aminobutyric acid (GABA) on GABA-A receptors. DE102007010077; 2008
  • Sanol Arznei Schwarz GmbH. Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders. EP1733727; 2006
  • Bioproject Soc Civ Ile. New arylpiperazine derivatives, useful to prevent and/or treat neuropsychiatric disorders e.g. disorders of drug dependence, sexual disorders and motor disturbance, are dopamine D3 receptor ligands. FR2878524; 2006
  • Bioproject Soc Civ Ile. Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor. EP1659112; 2006
  • Caldarone BJ, Harrist A, Cleary MA, et al. High affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 2004;56:657-64
  • Binder Eva Dkfm. New enantiomerically pure hexahydro-pyrrolo-cyclopenta-pyridine derivatives, useful as central nicotine receptor subtype agonists for e.g. treating Alzheimer's or Parkinson's disease, anxiety and depression. AT414305; 2006
  • Gruenenthal GmbH. New spiro-isoxazole-cycloalkane compounds, useful as vanilloid receptor 1 ligands for treating e.g. pain, depression and neurodegeneration. DE102005044814; 2006
  • Abbott GmbH & Co. KG. New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders. DE102005015957; 2006
  • Abbott GmbH & Co. KG. New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders. DE102005014628; 2006
  • Esteve Labor. Dr. New fused pyrazole derivatives, useful for treatment of psychosis and pain, are sigma receptor inhibitors. ES2251317; 2006
  • Sanofi Aventis Deutschland. Substituted 2 amino imidazoles, method for their manufacture and their use as a drug or diagnostic and drug containing them. EP1857445; 2007
  • Barden N, Shink E, Labbe M, et al. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:908-16
  • Lucini V, Spadoni G. Novel melatonin ligands having antidepressant activity as well as sleep inducing properties. CA2636601; 2007
  • Gobbi G, Mor M. Novel elatonin ligands having antidepressant activity as well as sleep inducing properties. EP1973868; 2008
  • Servier Lab. New 3-acylaminoethyl- 3-phenylthio-benzothiophene derivatives, are melatonin receptor ligands useful e.g. for treating sleeping disorders, anxiety, depression, jet lag or appetite disorders. FR2857011; 2005
  • Servier Lab. New indole derivatives are melatonin receptor binders useful to treat e.g. sleep disturbance, stress, anxiety, depression, cardiovascular diseases, digestive system disorders, schizophrenia, panic attack, obesity and insomnia. FR2907452; 2008
  • Servier Lab. New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them. EP1873140; 2008
  • Servier Lab. Use of agomelatin in the manufacture of a medicament for the treatment of bipolar disorders. EP1714647; 2006
  • Servier Lab. Use of agomelatine to obtain a medication aimed at treating generalised anxiety disorder. EP1842535; 2007
  • Servier Lab. Use of agomelatine to obtain a drug to treat Smith Magenis syndrome, major depression, seasonal depression, sleep disorder, cardiovascular disease, digestive system disorder, insomnia, shiftlag, appetite disorders and obesity. FR2908995; 2008
  • Chaki S, Okuyama S. Involvement of melanocortin-4 receptor in anxiety and depression. Peptides 2005;26:1952-64
  • Poitout L, Brault V. New 1,2,6-trisubstituted benzimidazole derivatives and imidazo-pyridine analogs, are melanocortin receptor ligands useful for treating e.g. obesity, cachexia, anxiety, depression or neuropathic pain. FR2862971; 2005
  • Chaki S, Oshida Y, Ogawa S, et al. MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol Biochem Behav 2005;82:621-6
  • Takeda Pharmaceutical. Antidepressant. PL371366; 2005
  • Takeda Pharmaceutical. Antidepressant. US2006241168; 2006
  • Bombardelli E, Morazzoni P. Use of hyperforin derivatives as an antidepressant agent. EP1607099; 2005
  • Boehringer Ingelheim Pharma. New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis. DE102004025552; 2005
  • Lodola A, Mor M, Rivara S, et al. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modeling. Chem Commun 2008;214-6
  • Sanofi Synthelabo. New 1-alkyl-(homo)piperazine-4-carboxylate ester derivatives, are fatty acid amidohydrolase inhibitors useful e.g. for treating pain, cancer or neurodegenerative, cardiovascular, inflammatory or allergic disease. FR2866888; 2005
  • Sanofi Synthelabo. Derivatives of arylalkylcarbamates, process for their preparation and therapeutic application thereof. EP1972616; 2008
  • Halene TB, Siegel SJ. PDE inhibitors in psychiatry – future options for dementia, depression and schizophrenia? Drug Discov Today 2007;12:870-8
  • Boehringer Ingelheim Pharma. New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease. DE102005023207; 2006
  • Boehringer Ingelheim Pharma. New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease. DE102005019718; 2006
  • Boehringer Ingelheim Pharma. New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease. DE102005035575; 2007
  • Boehringer Ingelheim Pharma. New substituted pteridine compounds, useful as phosphodiesterase 4 inhibitors for treating e.g. inflammatory diseases, cancer, asthma, ulcerative colitis, depression and schizophrenia. DE102004057645; 2006;
  • Servier Lab. New triazabenzo(a)naphtho(2,1,8-cde)azulene derivatives useful as tyrosine hydroxylase inducers, e.g. for treating depression or anxiety. FR2911141; 2008
  • Medtrack. Available from: http://www.medtrack.com/research/default.asp, Life Science Analytics, Inc

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.